Skip to content

Enterococcus faecalis and faecium reporting

Enterococcus antibiogram software for E. faecalis and E. faecium susceptibility by species and unit

A single Enterococcus line averages two organisms that behave nothing alike. Split faecalis from faecium, add VRE by unit, and have the table ready before the committee meets.

Read the short answer

Try the builder on the sample data, or drop in your own CSV. It is parsed in your browser and never uploaded.

Antibiogram Builder
Synthetic sample dataset
Parsed in this browser, never uploaded.

under 40 40 to 59 60 to 74 75 to 89 90 and over n<30, below the reporting threshold n/t, not tested on this panel

Short answer

An Enterococcus antibiogram reports, for first isolates per patient, the percent susceptible to ampicillin, vancomycin, linezolid, daptomycin and the urinary agents, separately for Enterococcus faecalis and Enterococcus faecium, with the isolate count beside every cell. Antimicrobe builds it from a lab CSV with no interface, hides the drugs enterococci are intrinsically resistant to, and flags any cell under 30 isolates. The cumulative table runs on the Lab plan from $249 a month, and unit cuts with quarterly VRE trends are on the Stewardship plan at $749 a month.

Computed from your own isolates, never from a national average.

Why one Enterococcus line misleads

Enterococcus faecalis is almost always ampicillin susceptible, while most Enterococcus faecium in US hospitals are ampicillin resistant and a large share are vancomycin resistant. Published hospital antibiograms show the gap year after year. When a lab reports "Enterococcus species" as one row, the ampicillin figure lands somewhere in the middle and describes neither organism. A prescriber choosing empiric therapy for an enterococcal bacteremia in the ICU needs to know which one the unit usually grows.

CLSI M39 asks for species-level reporting when the laboratory identifies to species, and most modern instruments do. The work is in the export: separating the rows, applying the first isolate rule to each species, and keeping the ones with too few isolates from printing a percentage that the committee will quote for a year.

  • E. faecalis and E. faecium in separate rows, other species grouped and counted
  • Ampicillin, vancomycin, linezolid and daptomycin for every species with enough isolates
  • Nitrofurantoin and fosfomycin on the urine cut, where they are actually used
  • VRE share by unit and quarter from the same upload
  • A flag on every cell under 30 isolates, with the raw count shown instead of a percentage

Drugs that should not appear on an Enterococcus report

Enterococci are intrinsically resistant to cephalosporins, clindamycin and low levels of aminoglycosides, and CLSI M100 warns that trimethoprim-sulfamethoxazole can look active in the laboratory while failing in patients. A spreadsheet that pulls every drug the instrument tested will print percentages for some of these, and a busy prescriber reads a number as permission. Antimicrobe suppresses intrinsic resistance by organism and lists the suppressed drugs in a footnote, so the table answers only the questions it can answer.

High-level gentamicin and streptomycin screens are a different case. They tell the team whether an aminoglycoside will add synergy to a cell wall agent in endocarditis, so they are reported as their own rows with their own counts. Daptomycin also needs care: CLSI revised the enterococcal daptomycin breakpoints in 2019 and introduced a susceptible dose dependent category for E. faecium, so a multi-year trend should state which definition each year used.

What goes in and what comes out.
Lab export field Enterococcus report output
Organism name E. faecalis, E. faecium and other species separated, intrinsic resistance suppressed
Specimen source, location, collection date Susceptibility by blood, urine and wound source, by unit, quarter and year
Drug, MIC or zone, S, I, SDD, R result Percent susceptible per drug, with the daptomycin category kept as reported
High-level aminoglycoside screen Synergy screen rows for gentamicin and streptomycin with counts
Patient ID One isolate per patient per species per analysis period

A worked example from a 250 bed hospital

Take 410 Enterococcus results in a year. After the first isolate rule, 302 patients remain: 236 E. faecalis, 58 E. faecium and 8 other species. A combined "Enterococcus species" row would show 247 of 302 ampicillin susceptible, 81.8 percent, which sounds reassuring. Split by species, E. faecalis is 231 of 236, 97.9 percent, and E. faecium is 13 of 58, 22.4 percent. Vancomycin follows the same pattern, 228 of 236 for faecalis and 21 of 58 for faecium, so 37 of the 58 faecium isolates are VRE.

Now filter to the two ICUs. Only 22 E. faecium isolates remain, under the 30 isolate threshold, so the report shows the count and suggests pooling two years instead of printing a fragile ICU percentage. The committee sees three facts it can act on: ampicillin is the right default for faecalis, faecium needs a different empiric plan, and the ICU VRE share needs another year of data before it is quoted. These numbers are illustrative arithmetic, not data from a customer.

Who buys this

The buyer is a stewardship pharmacist, infectious diseases physician or microbiology supervisor who has been asked whether the hospital's enterococcal numbers support its bacteremia and urinary guidance, and who today splits the species by hand once a year. For the quarterly VRE watch alongside MRSA and CRE, see infection prevention software for MDRO tracking. Unit tables are explained on ICU antibiogram software, and the companion organism cuts are on MRSA antibiogram software and Pseudomonas antibiogram software. The CDC lists vancomycin-resistant Enterococcus as a serious threat in its antimicrobial resistance threats report, estimating 54,500 cases among hospitalized patients and 5,400 deaths in 2017, and current breakpoints are published in CLSI M100. Plans and prices are on the pricing page.

What it does not do

Antimicrobe does not flag individual patients, page a pharmacist about a VRE bacteremia or recommend a dose. It reports what the laboratory has resulted, as cumulative tables and trends. Patient-level alerting belongs to a surveillance platform, and the tools that do it are compared in bug-drug mismatch software compared.

Related reading: hospital antibiogram software, urine antibiogram and UTI resistance rates, carbapenem-resistant organisms reporting, MRSA tracking software for infection prevention. The four steps from susceptibility testing data to an antibiogram cover the method end to end.

Questions

On this page's topic

What is an Enterococcus antibiogram?

It is a cumulative susceptibility report for Enterococcus that shows the percentage of first isolates per patient susceptible to ampicillin, vancomycin, linezolid, daptomycin and urinary agents, ideally split into E. faecalis and E. faecium, with isolate counts. It guides empiric therapy before a patient's own result is back.

Should E. faecalis and E. faecium be reported separately?

Yes, when the laboratory identifies to species, and CLSI M39 recommends it. E. faecalis is almost always ampicillin susceptible while most hospital E. faecium are not, so a combined row hides the difference that drives empiric choices. Antimicrobe splits them automatically from the organism name.

Can Antimicrobe report VRE by unit?

Yes. Unit and specimen filters run on the same dataset, so the VRE share by ICU or ward and by quarter comes from one upload. Cells under 30 isolates show the raw count instead of a percentage. Unit cuts and quarterly trends are part of the Stewardship plan.

Does it need an interface to our laboratory system?

No. Your lab exports a susceptibility line list as CSV, you upload it and map the columns once. Most hospitals produce the first Enterococcus table on the day they start.

More on antimicrobial resistance reporting

  • CLSI breakpoints A breakpoint revision can move a susceptibility rate by several points without one organism...
  • WHONET WHONET is good software, it is free, and it is the global default for a reason. Most US team...
  • TheraDoc competitors Most teams shopping for a TheraDoc alternative are not unhappy with the alerts. They are at...
  • Sentri7 alternatives Sentri7 took two segments in the 2026 Best in KLAS report, so most teams looking for an alte...
  • MedMined alternatives MedMined is now BD HealthSight Infection Advisor, sold next to BD HealthSight Clinical Advis...
  • VigiLanz alternatives VigiLanz is sold by Inovalon in three hospital tiers now, and the antibiogram sits in the to...

Start with your own export

See your own resistance picture, cut the way you actually work

Build the antibiogram on the synthetic sample dataset, or drop in your own CSV and watch it parse without leaving your browser. When you want an account, one email address is the whole sign-up.

Your file is parsed in your browser and never uploaded. No card required.